225
Participants
Start Date
April 19, 2022
Primary Completion Date
April 30, 2026
Study Completion Date
April 30, 2026
Imlifidase
Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.
Normal Transplantation Routine
Transplantation and pre- and post-transplantation therapies in accordance with the clinic's normal transplantation routine.
Department of Nephrology , Zaloška 7, Ljubljana
Medizinische Universitaet Wien, Vienna
UZ Leuven - Campus Gasthuisberg, Leuven
University Medical Center Groningen, Groningen
Charité - Universitätsmedizin Berlin, Berlin
Hospital 12 de Octubre, Madrid
Azienda Ospedaliera di Padova, Padua
CHU de Grenoble - Hôpital Michallon, La Tronche
Azienda Ospedaliero - Universitaria di Parma, Parma
Hôpital Necker - Enfants Malades, Paris
Centre Hospitalier Universitaire (CHU) de Rouen - Hôpital de Bois-Guillaume, Bois-Guillaume
Klinikum rechts der Isar der Technische Universitaet Muenchen, Munich
Institut klinicke a experimentalni mediciny (IKEM), Prague
Leiden University Medical Center, Leiden
Erasmus University Medical Center, Rotterdam
Hospital Del Mar, Servicio de Nefrología, Barcelona
Hospital Clínic de Barcelona, Unidad de Trasplante Renal, Barcelona
Vall d'Hebron University Hospital (HUVH), Barcelona
Karolinska University Hospital, Huddinge
Uppsala University Hospital, Uppsala
St. James University Hospital, Leeds
Leicester General Hospital, Leicester
Lead Sponsor
Hansa Biopharma AB
INDUSTRY